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ABSTRACT
Cancer-associated isocitrate dehydrogenase (IDH) 1 and 2 mutations gain a 
new activity of reducing α-KG to produce D-2-hydroxyglutarate (D-2-HG), which is 
proposed to function as an oncometabolite by inhibiting α-KG dependent dioxygenases. 
We investigated the function of D-2-HG in tumorigenesis using IDH1 and IDH2 mutant 
cancer cell lines. Inhibition of D-2-HG production either by specific deletion of the 
mutant IDH1-R132C allele or overexpression of D-2-hydroxyglutarate dehydrogenase 
(D2HGDH) increases α-KG and related metabolites, restores the activity of some 
α-KG-dependent dioxygenases, and selectively alters gene expression. Ablation 
of D-2-HG production has no significant effect on cell proliferation and migration, 
but strongly inhibits anchorage independent growth in vitro and tumor growth in 
xenografted mouse models. Our study identifies a new activity of oncometabolite 
D-2-HG in promoting tumorigenesis.
INTRODUCTION
Reprogramming of cellular metabolism has long 
been hypothesized as one of the key processes during 
tumorigenesis. It was noted by Otto Warburg that 
anomalous energy metabolism of high aerobic glycolysis 
was favored by cancer cells [1]. The underlying molecular 
mechanism for altered metabolic regulation in cancer cells 
is much more complicated than expected. To data, there is 
still some debate as to how metabolism is altered in tumor 
cells and whether the metabolic switch contributes to, or is 
merely a consequence of, tumorigenesis. Recent discoveries 
in the mutations of isocitrate dehydrogenases 1/2 (IDH1/2) 
in a large number of human cancers have provided a 
direct link between altered metabolism and cellular 
transformation and tumorigenesis [2–6]. The mutant 
IDH1/2 found in human cancer not only have lost their 
normal catalytic activity but also conferred a neomorphic 
enzymatic gain-of-function: the NADPH-dependent 
reduction of α-KG to D-2-hydroxyglutarate (D-2-HG), a 
trace metabolite in normal cells [7, 8]. Astonishingly, D-2-
HG accumulates to as high as 5 – 35 μmol/g (or 5 – 35 
mM) in cases of glioma harboring IDH1/2 mutations [7–
10]. Taking advantage of its abnormally high accumulation, 
detecting D-2-HG by magnetic resonance spectroscopy has 
become an effective way to detect solid tumors harboring 
IDH1/2 mutations [11, 12].
The cancer-associated mutant IDH1 or IDH2 
exclusively produces D-2-HG, but not L-2-HG [7, 8], 
both of which are byproducts of normal mitochondrial 
metabolism [13]. To protect cells from high accumulation 
of 2-HG, there are two FAD-dependent mitochondrial 
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enzymes, D-2-HG dehydrogenase (D2HGDH) and L-2-
HG dehydrogenase (L2HGDH), which catalyzes the 
conversion of harmful D-2-HG and L-2-HG to α-KG 
[14–16], respectively. Loss-of-function mutations in 
D2HGDH or L2HGDH in human cause organic aciduria, 
as characterized by the high accumulation of D-2-HG or 
L-2-HG in the urine, respectively [17]. These observations 
reaffirm the importance of keeping a low level of 2-HG.
Numerous studies have been conducted aiming 
to understand the function of IDH mutations in cancer, 
and several hypotheses have been proposed. It has been 
suggested that IDH mutations change the redox state 
of cells [18], given that mutant IDH1/2 use NAPDH as 
a co-factor to catalyze the conversion of α-KG to D-2-
HG. More importantly, emerging evidence suggests that 
IDH mutation derived D-2-HG acts as an oncometabolite 
to promote cellular transformation, at least in part by 
inhibiting members of the α-KG-dependent dioxygenase 
family. We have previously reported that 2-HG functions 
as an inhibitor towards α-KG-dependent dioxygenases, 
because D-2-HG is structurally similar to α-KG and can 
bind to the α-KG binding pocket in these enzymes [19]. 
In agreement, in vitro studies have revealed that D-2-
HG inhibits the activity of multiple α-KG-dependent 
enzymes with a wide range of potencies [19, 20]. Among 
these α-KG-dependent dioxygenases, the JmjC domain-
containing histone demethylases (KDMs) and the TET 
(ten-eleven translocation) family of DNA hydroxylases 
have emerged as the two major targets of D-2-HG 
produced by mutant IDH in promoting tumorigenesis [21].
D-2-HG was reported to promote cytokine-
independent growth and block erythropoietin (EPO)-
induced differentiation, two properties obligatory 
for leukemogenesis, in a cell culture model [22]. 
Notably, depletion of TET2 also induces growth factor 
independence and blocks cellular differentiation in TF-1 
cells [22]. However, the leukemic transformation is 
potentiated by cell-permeable D-2-HG, but not L-2-HG. It 
is unclear why L-2-HG, which is a more potent inhibitor of 
TET2 and many other α-KG-dependent enzymes than D-2-
HG, is ineffective in promoting oncogenic transformation. 
It has also been reported that mutant IDH or either cell 
permeable D-2-HG or L-2-HG treatment could lead to the 
suppression of HNF-4α (a master regulator of hepatocyte 
identity and quiescence), which is associated with a 
reduction in histone H3 lysine4 trimethylation (H3K4me3) 
in its promoter, and block hepatocyte differentiation from 
progenitors [23]. These data suggest that the oncogenic 
targets of mutant IDH1/2 might be tumor type specific.
Although the overwhelming genetic evidence of 
IDH mutation in human cancer unequivocally supports 
a role of D-2-HG in tumorigenesis, some key questions, 
such as whether D-2-HG is required only for initiation 
and/or maintenance of tumorigenic potential, have not 
been satisfactorily answered. This is because much of 
previous studies were done using either pharmacological 
approaches of adding cell permeable D-2-HG or IDH 
inhibitors or ectopic expression of mutant IDH in already 
established cancer lines. In this study, we use genetic 
approach to interrogate the function of D-2-HG using 
tumor cell lines that naturally harboring the mutant 
IDH genes. Our results show that D-2-HG levels do 
not significantly affect cell growth or proliferation, but 
are critically important in maintaining the tumorigenic 
property of the mutant IDH-containing cancer cells.
RESULTS
D2HGDH overexpression reduces D-2-HG level 
in IDH-mutated cancer cells
Previous studies using cell permeable D-2-HG 
analogs or mutant IDH inhibitors have the limitation 
of possible nonspecific effects associated with all 
pharmacological agents. Moreover, ectopic expression of 
mutant IDH in established cell lines or even cancer cells 
may not be pathologically relevant because these cells 
were transformed through a pathway that is independent 
of IDH mutation. Therefore, expression of mutant 
IDH in these cells does not necessarily recapitulate 
the oncogenesis process caused by IDH mutations. To 
determine the function of D-2-HG in cancer cells, we 
aimed to eliminate D-2-HG in human cancer cells that 
contain a mutant IDH1 or IDH2 allele. Searching of 
the Cancer Cell Line Encyclopedia (CCLE) database 
identified two human sarcoma cell lines, HT1080 and 
SW1353, which contain IDH1R132C and IDH2R172S, res-
pectively. By sequencing of genomic DNA, we confirmed 
the missense mutations of IDH1 Arg-132-Cys (R132C) 
and IDH2 Arg-172-Ser (R172S) in HT1080 and SW1353 
cells, respectively (Figure S1). Consistently, gas chro-
matography and mass spectrometry (GC-MS) analysis 
demonstrated that 2-HG was accumulated to high levels in 
both HT1080 and SW1353 cells (Figures S2A and S2C).
To determine the effect of D-2-HG, we removed 
D-2HG in the IDH1 mutant HT1080 cells by two different 
approaches, overexpression of D2HGDH and deletion of 
the mutant IDH1R132C allele. We infected the cells with 
retrovirus expressing Flag-tagged human D2HGDH. We 
found that stable overexpression of wild-type D2HGDH 
significantly (p < 0.001) reduced 2-HG levels by 67% in 
HT1080 cells (Figures S2B and 1B). We also examined 
two D2HGDH mutants, P189L and G477R, found in 
aciduria patients. Expression of either mutant to a level 
similar as the wild type D2HGDH failed to reduce 2-HG 
levels in HT1080 cells (Figure 1B), demonstrating that 
the patient-associated D2HGDH mutants are catalytically 
inactive and the D2HGDH enzyme activity is necessary 
and sufficient to reduce D-2-HG in HT1080. Moreover, 
stable overexpression of wild-type D2HGDH, but not 
the P189L or G477R mutant, greatly decreased 2-HG 
levels by 99.9% in SW1353 cells (Figures 1B and 
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S2D). Although the precise mechanism why D-2HG 
was much more efficiently reduced in SW1353 than in 
HT1080 is unclear, the different subcellular localization 
of IDH1 and IDH2 might contribute to this difference. 
The mutant IDH1 in HT1080 is in cytoplasm while the 
mutant IDH2 in SW1353 is in mitochondria. Therefore, 
the mitochondrially produced D-2-HG may be more 
efficiently metabolized by the mitochondrially localized 
D2HGDH in SW1353 cells
In addition to D-2-HG reduction, we found that 
stable overexpression of D2HGDH also led to a significant 
increment of α-KG levels in both HT1080 cells (increased 
by 1.49-fold; p < 0.05) and SW1353 cells (increased by 
1.53-fold; p < 0.01) (Figure 1C), confirming the function 
of D2HGDH in converting D-2-HG to α-KG. It is known 
that α-KG acts not only as a key intermediate in the TCA 
cycle for energy metabolism but also as an entry point 
for amino acids to enter the TCA cycle (anaplerosis) 
(Figure 1A). Supporting this notion, we found that in 
parallel with increased α-KG levels, intracellular levels of 
citrate and isocitrate, which are the upstream metabolites 
of α-KG in the TCA cycle, were significantly increased 
in both HT1080 and SW1353 cells stably overexpressing 
D2HGDH (increased by 1.22-fold; p < 0.05 and 1.51-
fold; p < 0.01, respectively) (Figure 1C). Additionally, 
intracellular levels of downstream metabolites of α-KG 
in the TCA cycle and its anaplerosis were significantly 
increased in SW1353 cells stably overexpressing 
D2HGDH, including succinate (increased by 1.70-fold; 
p < 0.01), glutamate (increased by 1.38-fold; p < 0.01), and 
glutamine (increased by 1.30-fold; p < 0.01) (Figure 1C). 
Such increases were, however, not observed in HT1080 
cells stably overexpressing D2HGDH (Figure 1C). These 
findings thus suggest that ectopic expression of D2HGDH 
in IDH1/2-mutated cells can reduce D-2-HG level through 
facilitating the conversion of D-2-HG to α-KG.
To examine the specificity of 2HGDH, we expressed 
the human L2HGDH in both HT1080 and SW1353 cells. 
Stable overexpression of L2HGDH failed to reduce 
2-HG level in both cell types in which the endogenous 
mutant IDH1 exclusively produces D-2-HG (Figure 1D), 
demonstrating that the effect of D/L-2HGDH on reducing 
2-HG is chiral-specific.
D2HGDH overexpression restores the activity of 
several α-KG-dependent dioxygenases
We and others have previously shown that D-2-
HG acts as an α-KG antagonist to inhibit the activity 
of α-KG-dependent dioxygenases [19, 20, 24]. We next 
set out to investigate whether D-2-HG clearance by 
D2HGDH overexpression could restore the activity of 
α-KG-dependent dioxygenases in IDH-mutated cells. 
We examined the enzyme activity of PHDs and C-P4Hs 
in HT1080 and SW1353 cells by measuring their 
physiological substrates. Our data showed that D2HGDH 
overexpression in HT1080 and SW1353 cells did not 
change the protein level of HIF-1α, the substrate of PHDs 
[25] (Figures S3A and S3B). The PHD inhibitors, such 
as CoCl2, DFO, or DMOG, were included as positive 
controls. Moreover, we found that overexpression of 
D2HGDH in HT1080 and SW1353 cells did not change 
the protein level of Endostatin, the product of C-P4H 
enzymes (Figure S4). These results suggest that D-2-HG 
reduction by D2HGDH overexpression in IDH1/2-mutated 
cells had no significant effect on the activity of PHD and 
C-P4H enzymes.
It has previously been shown that D-2-HG can 
inhibit the hydroxylation and maturation of collagen type 
IV, leading to an increased level of soluble immature 
collagen type IV in brain specific IDH1-R132H knock-
in mice [26]. We found that HT1080 cell produced more 
immature collagen type IV than SW1353 cells. Stable 
overexpression of D2HGDH significantly decreased the 
level of soluble collagen type IV in HT1080 cells, but 
not in SW1353 cells (Figure 2A), indicating that collagen 
hydroxylation in HT1080 cells is sensitive to D-2-HG. 
The reduction of immature collagen type IV by D2HGDH 
expression is consistent with an increased collagen 
hydroxylation activity.
D-2-HG is also known to inhibit the JmjC domain 
containing histone demethylases and the TET family 
5mC hydroxylases, two potential targets of IDH1/2 
mutations involved in epigenetic regulation [21]. We next 
investigated the effect of D-2-HG reduction by D2HGDH 
overexpression on histone and DNA methylation. We 
found that stable overexpression of D2HGDH in SW1353 
cells preferentially decreased the levels of H3K9me2 
and H3K9me3, two repressive histone methylation 
markers, whereas methylation of H3K4me2, H3K27me2, 
H3K27me3 or H3K79me2 was not significantly changed 
(Figure 2B). Notably, such alterations in histone 
methylation markers were, however, not observed in 
HT1080 cells after stable overexpression of D2HGDH 
(Figure 2B). It is worth noting that the D-2-HG levels in 
D2HGDH overexpressing HT1080 cells were much higher 
than D2HGDH overexpressing SW1353 cells (Figure 
1B). A possible explanation is that although reduced, 
the remaining D-2HG in D2HGDH overexpressing 
HT1080 cells might still be sufficiently high to inhibit 
demethylation of H3K9me2 and H3K9me3.
The TET family of DNA hydroxylases catalyze 
three-sequential oxidation reactions of 5-methylcytosine 
(5mC) and play an essential role in active DNA 
demethylation [27]. 5-hydroxymethylcytosine (5 hmC) is 
the first hydroxylation intermediate generated from 5mC 
by TET enzymes. Genomic 5 hmC level in most cultured 
cells is normally very low, but it can be substantially 
increased by expression of the catalytic domain of TET2 
(TET2CD) and thus can be easily detected by dot-blot using 
an antibody specifically recognizing 5 hmC [27–29]. We 
found that transient overexpression of TET2CD, but not the 
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Figure 1: Ectopic expression of D2HGDH reduces D-2-HG in IDH-mutated cancer cells. (A) A scheme of metabolic 
pathways involved in D-2-HG metabolism. (B) D2HGDH overexpression reduces D-2-HG production in IDH mutant cells. Flag-tagged 
wild-type or mutant D2HGDH was stably overexpressed in HT1080 and SW1353 cells as indicated. The ectopically expressed proteins 
were determined by western blot analysis (left panel). Tubulin was used as a loading control. The intracellular concentration of 2-HG was 
determined by GC-MS analysis as described in “Method” (middle and right panels). (C) D2HGDH overexpression increases α-KG levels 
in IDH mutant cells. Intracellular concentrations of α-KG and other metabolites were determined by GC-MS analysis. (D) The effect of 
2HGDH on reducing 2-HG is chiral-specific. Flag-tagged D2HGDH or L2HGDH was stably overexpressed in HT1080 and SW1353 
cells. The ectopically expressed protein levels were determined by western blot analysis. The L2HGDH antibody likely recognizes the 
endogenous protein. Shown are average values with standard error (SEM) of triplicated experiments. *denotes p < 0.05, **denotes p < 0.01, 
and ***denotes p < 0.001 for the indicated comparison.
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Figure 2: Ectopic expression of D2HGDH restores the activity of several α-KG-dependent dioxygenases. (A) D2HGDH 
overexpression promotes the maturation of Collagen Type IV. Flag-tagged D2HGDH was stably overexpressed in HT1080 and SW1353 
cells. In these stable cells, soluble collagen Type IV, which indicates the immature collagen, was detected by western blotting under 
reducing conditions with a collagen Type IV antibody. (B) D2HGDH overexpression decreases the levels of H3K9me2 and H3K9me3 
in SW1353 cells, but not in HT1080 cells. Flag-tagged D2HGDH was stably overexpressed in HT1080 and SW1353 cells. Levels of 
various histone lysine methylations were detected by western blotting with specific antibodies. Total H3 was used as a loading control. 
(C) D2HGDH increases genomic 5 hmC levels in TET2 expressing cells. Flag-tagged D2HGDH was stably overexpressed in HT1080 
and SW1353 cells, and these stable cells were transiently transfected with plasmids of wild-type TET2CD or its catalytic inactive mutant 
TET2CM as indicated. Forty-eight hours after transient transfection, genomic DNA was isolated, and 5 hmC was determined by dot-blot 
analyses. Methylene blue staining was performed to control equal DNA loading. The levels of transiently expressed Flag-tagged proteins 
were determined by western blot analysis (left panels).
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catalytic mutant TET2 (TET2CM), significantly increased 
genomic 5 hmC in both HT1080 and SW1353 cells (Figure 
2C). Interestingly, transient overexpression of TET2CD in 
SW1353 cells stably overexpressing D2HGDH led to 
higher levels of genomic 5 hmC than control cells (Figure 
2C). Such a change in genomic 5 hmC was, however, 
not observed in HT1080 cells co-expressing TET2CD and 
D2HGDH (Figure 2C). Collectively, our data suggest 
that D-2-HG reduction by D2HGDH overexpression can 
potentiate the activity of some histone demethylases and 
TET2 in the IDH2-mutated SW1353 cells. The lack of 
effect in HT1080 cells could be due to a less effective 
reduction of D-2-HG by D-2HGDH expression, and 
therefore the remaining D-2-HG might be still sufficient 
to inhibit the ectopically expressed TET2CD.
Knockout of mutant IDH1-R132C allele 
eliminates D-2-HG and increases α-KG and its 
related metabolites
As described above, D2HGDH overexpression had 
little effect on changing epigenetic markers in HT1080 
cells. This promoted us to test whether the incapability of 
D2HGDH overexpression to affect the activity of histone 
and DNA demethylases in HT1080 cells is attributed to an 
incomplete clearance of D-2-HG. To achieve a complete 
D-2-HG clearance, we applied the TALEN technology 
to generate HT1080 cells with knock-out of endogenous 
IDH1-R132C (HT1080/IDH1+/–). After screening 213 
clones, we isolated one clone with deletion of the mutant 
IDH1 R132C. In this clone, a frame-shift mutation in 
IDH1-R132C copy was confirmed by genomic sequencing 
(Figure 3A). As a result, IDH1 protein expression was 
decreased (Figure S6), and D-2-HG production was 
completely eliminated in HT1080/IDH1+/– cells (Figures 
3B and S5A and S5B).
To avoid the caveats of possible off-target effect of 
TALEN, we re-expressed mutant IDH1 in the HT1080/
IDH1+/– cells. As expected, re-introduction of IDH1-
R132C mutant into HT1080/IDH1+/– cells could restore 
D-2-HG to a level similar as the parental HT1080 cells 
(Figure 3B). As a negative control, re-expression of IDH1-
R132C/T77A double mutant, which eliminated the D-2-
HG producing activity, could not accumulate D-2-HG in 
HT1080/IDH1+/– cells (Figure 3B).
Metabolic profiling analysis revealed that the α-KG 
level was significantly lower in HT1080/IDH1+/– cells 
re-expressing IDH1-R132C mutant than cells re-expressing 
IDH1-R132C/T77A double mutant (decreased by 46%; 
p < 0.001) (Figure 3C). Additionally, intracellular levels 
of upstream metabolites of α-KG in the TCA cycle as well 
as certain downstream metabolites of α-KG in anaplerosis 
were also significantly decreased in HT1080/IDH1+/– cells 
re-expressing IDH1-R132C mutant, including citrate/
isocitrate (decreased by 49%; p < 0.05) and glutamate 
(decreased by 20%; p < 0.01) (Figure 3C).
Given that IDH1-R132C mutant uses NADPH 
as a co-factor to convert α-KG to D-2-HG, we next 
investigated whether IDH1-R132C mutation would affect 
cellular NADPH homeostasis. We found that there was 
no difference in the ratio of NADPH/NADP+ between 
HT1080/IDH1+/– cells re-expressing IDH1-R132C 
mutant and those re-expressing IDH1-R132C/T77A 
double mutant (Figure S7A). In agreement, the ratio of 
GSH/GSSG was identical between the two cell lines 
(Figure S7B). Together, these data suggest that putting-
back IDH1-R132C mutant in HT1080/IDH1+/– cells does 
not affect cellular NADPH homeostasis and the redox 
potential although α-KG and its immediate neighboring 
metabolites are changed.
Cellular D-2-HG suppresses the activity of 
several α-KG-dependent dioxygenases
We next studied whether putting-back IDH1-
R132C mutant in HT1080/IDH1+/– cells could affect the 
activity of α-KG-dependent dioxygenases. We examined 
the substrates of several α-KG dependent dioxygenases 
and found that re-introduction of IDH1-R132C mutant 
in HT1080/IDH1+/– cells did not affect the protein 
levels of HIF-1α (Figure S8A and S8B) and Endostatin 
(Figure S9) when compared to those cells re-expressing 
IDH1-R132C/T77A double mutant. In contrast, putting-
back IDH1-R132C mutant in HT1080/IDH1+/– cells 
increased the level of soluble immature collagen type 
IV when compared to those cells re-expressing IDH1-
R132C/T77A double mutant (Figure 3D). Furthermore, 
re-introduction of IDH1-R132C mutant in HT1080/
IDH1+/– cells increased the levels of H3K9me2 and 
H3K9me3 when compared to cells re-expressing IDH1-
R132C/T77A double mutant (Figure 3E), indicating that 
IDH1-R132C mutant / D-2-HG can inhibit the activity 
of histone demethylases responsible for demethylation 
of H3K9me2/3. Additionally, the mutant IDH1 putting-
back HT1080/IDH1+/– cells transiently overexpressing 
TET2CD exhibited lower levels of genomic 5 hmC than 
the IDH1-R132C/T77A double mutant expressing cells 
(Figure 3F), suggesting that IDH1-R132C mutant/D-
2-HG can inhibit the activity of TET enzymes. Taken 
together, these findings suggest that D-2-HG in HT1080 
cells plays a role in cellular regulation by inhibiting α-KG 
dependent dioxygenases, particularly those involved in 
collagen maturation, DNA demethylation, and H3K9 
demethylation.
D-2-HG accumulation is associated with selective 
regulation of gene expression in HT1080 cells
IDH mutation has been reported to be associated 
with global hypermethylation (in both histone and CpG) 
and altered gene expression in acute myeloid leukemia 
(AML) and cholangiocarcinoma [30]. Mechanistically, 
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Figure 3: Putting-back IDH1-R132C in HT1080/IDH1+/– cells restores D-2-HG and inhibits the activity of several 
α-KG-dependent dioxygenases. (A–B) Deletion of the mutant IDH1-R132C allele in HT1080 cells eliminates D-2-HG production. 
The TALEN technology was applied to generate HT1080 cells with knock-out of endogenous IDH1-R132C (HT1080/IDH1+/–). Genomic 
sequencing confirmed the frame-shift mutation in IDH1-R132C allele, while the wild type IDH1 allele was intact (A). In accord, D-2-HG 
production was abolished in HT1080/IDH1+/– cells as determined by GC-MS analysis (B). (C) Putting-back IDH1-R132C in HT1080/
IDH1+/– cells decreases the levels of α-KG and its neighboring metabolites. The intracellular concentrations of α-KG and other metabolites 
as indicated were determined by GC-MS analysis as described in “Method”. (D) Putting-back IDH1-R132C in HT1080/IDH1+/– cells 
restores D-2-HG and inhibits the maturation of Collagen Type IV. Soluble immature collagen IV protein was detected by western blotting. 
(E) Putting-back IDH1-R132C in HT1080/IDH1+/– cells increases the levels of H3K9me2 and H3K9me3. Histone lysine methylation was 
determined by western blotting with specific antibodies as indicated. Total H3 was used as a loading control. (F) Putting-back IDH1-R132C 
in HT1080/IDH1+/– cells decreases genomic 5 hmC. In HT1080/IDH1+/– cells re-expressing cells, wild-type TET2CD or its catalytic inactive 
mutant TET2CM was transiently expressed. Forty-eight hours after transfection, genomic DNA was isolated, and 5 hmC was determined by 
dot-blot analyses. Methylene blue staining was performed to control equal DNA loading. The levels of transiently expressed Flag-tagged 
proteins were determined by western blot analysis (left panel). For (B) and (C), shown are average values with standard error (SEM) of 
triplicated experiments. *denotes p < 0.05, **denotes p < 0.01, and ***denotes p < 0.001 for the indicated comparison.
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D-2-HG produced by mutant IDH can alter epigenetic 
modifications by inhibiting α-KG-dependent histone and 
DNA demethylases [19]. These epigenetic changes may 
directly influence the chromatin status and transcription 
factor recruitment to modulate gene expression [31, 
32]. As shown earlier in this study, D-2-HG is highly 
accumulated in HT1080/IDH1+/– cells re-expressing 
IDH1-R132C mutant, but not in HT1080/IDH1+/– cells 
re-expressing an empty vector, wild-type IDH1, or IDH1-
R132C/T77A double mutant (Figure 3B). Importantly, 
RNA sequencing analysis revealed that HT1080/IDH1+/– 
cells re-expressing IDH1-R132C mutant formed a cluster 
distinct from the other clusters containing HT1080/
IDH1+/– cells re-expressing an empty vector, wild-type 
IDH1, or IDH1-R132C/T77A double mutant (Figure 4A), 
further supporting the notion that D-2-HG accumulation is 
associated with changes in gene expression.
Surprisingly, there were only selective groups of 
genes whose transcriptional expression were different 
between HT1080/IDH1+/– cells re-expressing IDH1-
R132C mutant and the HT1080/IDH1+/– cells re-expressing 
an empty vector, wild-type IDH1, or IDH1-R132C/T77A 
double mutant (Figure 4B). Interestingly, we detected 
significant up-regulation of genes involved in endoplasmic 
reticulum (ER), protein folding, and secretion in cells with 
D-2-HG production (Figure 4C). On the other hand, genes 
involved in extracellular matrix pathways are reduced. 
Although the detailed mechanism for these changes is 
unclear, our data suggest a potential role of D-2-HG in 
these cellular processes.
D-2-HG does not affect cell proliferation but 
promotes anchorage independent growth in vitro 
and tumor growth in vivo
By using genetically modified HT1080 cell lines 
described above, we examined the effect of D-2-HG on 
cell proliferation. Surprisingly, the rate of cell proliferation 
was identical between HT1080/IDH1+/– cells re-expressing 
IDH1-R132C mutant and re-expressing IDH1-R132C/
T77A double mutant (Figure 5A). It is possible that the 
epigenetic effect of D-2-HG accumulation on cell growth 
might be a slow process. Therefore, we had cultured the 
cell lines for over 20 passages, but still did not observe 
any obvious effect of D-2-HG accumulation on cell 
proliferation (data not show). Similarly, there was no 
difference in the rate of cell proliferation between stable 
HT1080 cells overexpressing D2HGDH and control 
cells expressing an empty vector (Figure 5A), further 
supporting the notion that D-2-HG does not directly 
impact cell proliferation, at least in HT1080 cells.
Next, we tested whether D-2-HG may affect cell 
migration. In vitro scratch assay revealed that there 
was no difference in cell migration between HT1080/
IDH1+/– cells re-expressing IDH1-R132C mutant and 
those re-expressing IDH1-R132C/T77A double mutant 
(Figure S10). Likewise, no visible difference was observed 
in cell motility during wound healing assays between 
HT1080 cells stably overexpressing D2HGDH and control 
cells expressing an empty vector (Figure S10). These 
results suggest that D-2-HG does not affect cell migration 
in HT1080 cells.
It is well established that anchorage-independent 
cell growth is a fundamental property of cancer cells. 
The ability of anchorage independent growth tightly 
correlates with tumorigenic and metastatic potentials in 
vivo. Strikingly, we found that re-introduction of IDH1-
R132C mutant in HT1080/IDH1+/– cells dramatically 
(p <0.001) increased the cell’s ability to exhibit anchorage 
independent growth compared to those re-expressing 
IDH1-R132C/T77A double mutant (Figure 5B). Moreover, 
D2HDGH overexpression also reduced the ability of 
HT1080 cells to exhibit anchorage independent cell growth 
(p < 0.001) (Figure 5B), even though the reduction of D-2-
HG in these cells was incomplete (Figure 1B). These data 
suggest that D-2-HG plays an important role in promoting 
anchorage-independent cell growth in HT1080 cells.
The effect of D-2-HG on stimulating anchorage-
independent cell growth led us to test whether D-2-
HG renders growth advantage to tumor cells in vivo. 
We performed xenograft experiments using HT1080/
IDH1+/– cells re-expressing IDH1-R132C mutant or those 
re-expressing IDH1-R132C/T77A double mutant. Tumor 
growth was monitored over a period of 20–25 days. 
Our data demonstrated that the tumor volumes in nude 
mice injected with HT1080/IDH1+/– cells re-expressing 
IDH1-R132C were significantly larger than those from 
mice injected with HT1080/IDH1+/– cells re-expressing 
IDH1-R132C/T77A double mutant (Tumor size at 25 
days: 204 ± 33 mm3 vs. 67 ± 25 mm3 for IDH1-R132C 
vs. IDH1-R132C/T77A; p = 0.0045) (Figure 5C). Finally, 
we performed similar xenograft experiments using stable 
HT1080 cells with or without ectopic expression of 
D2HGDH. Again, tumor cell growth was dramatically 
suppressed by the expression of D2HGDH (Tumor size 
at 25 days: 343 ± 52 mm3 vs. 76 ± 22 mm3 for D2HGDH 
vs. Vec; p = 0.0002) (Figure 5C). Collectively, these data 
support a notion that D-2-HG promotes the tumorigenicity 
of HT1080 cells in vivo. Furthermore, even a three-fold 
reduction of D-2-HG was sufficient to suppress tumor 
growth of IDH1-mutated HT1080 cells.
DISCUSSION
Mutations in IDH1 or IDH2 are frequently observed 
in human cancers, particularly with high frequency 
in secondary glioma, acute myeloid leukemia, and 
chondrosarcoma [2–4]. The exact mechanism regarding 
how IDH mutations promote tumorigenesis is not fully 
understood, because much of previous mechanistic studies 
have been heavily relying on overexpression or knock-in 
of mutant IDH in tumor cell lines that naturally do not 
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Figure 4: D-2-HG accumulation is associated with selective regulation of gene expression in HT1080 cells. HT1080/
IDH1+/– cells putting-back empty vector (Vec), wild-type IDH1 (IDH1), D-2-HG producing related mutant IDH1 (IDH1-R132C) and 
enzymatic inactive double mutant IDH1 (IDH1-R132C-T77A) were used for gene expression profiling. Hierarchically clustering of cell 
lines based on gene expression are shown in (A). The differentially expressed genes among the indicated clustered groups are presented in 
(B). The functional annotation enrichment of up- and down-regulated pathways is listed in (C).
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Figure 5: D-2-HG production is required for anchorage independent growth in vitro and tumor growth in vivo.  
(A) D-2-HG does not affect cell proliferation. Growth curves of HT1080/IDH1+/– cells with IDH1 putting-back (left panel) or HT1080 with 
D2GHDH overexpression (right panel) were determined. (B) D-2-HG promotes anchorage independent growth of HT1080 cells. HT1080/
IDH1+/– putting-back cells or HT1080 cell pools stably overexpressing Flag-D2HGDH were seeded in 6-well plates, and soft-agar colony 
formation assay was performed. Representative plates are shown. Quantification of colony numbers was derived from three independent 
experiments. (C) D-2-HG is required for tumor growth of HT1080 cells. HT1080/IDH1+/– putting-back cells or HT1080 cell pools stably 
overexpressing Flag-D2HGDH (2*106 cell) were injected subcutaneously into the flanks of nude mice. The tumor volume was carefully 
monitored during a period of 20–25 days after injection. In the end, tumors were extracted, photographed and weighted. Shown are average 
values with standard error (SEM) of triplicated experiments. **denotes p < 0.01 and ***denotes p < 0.001 for the indicated comparison.
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have native IDH mutations, and their cancer growth 
property may not depend on the ectopically expressed 
mutant IDH1/2. It is therefore difficult to ascertain the 
role of IDH mutations in tumorigenesis. In this report, we 
have used sarcoma cell lines HT1080 and SW1353 that 
contain endogenous mutations of IDH1/2 to investigate 
the function of IDH mutation in tumorigenesis. Previous 
studies have suggested that the oncometabolite D-2-
HG produced by cancer-associated mutant IDH1/2 may 
convey oncogenic signals through altering epigenetic 
modifications, which leads to altered gene expression 
and growth promotion [19, 20, 33, 34]. We manipulated 
D-2-HG levels in HT1080 and SW1353 cells by either 
stable overexpression of D2HGDH or knocking-out of the 
endogenous mutant IDH1 gene.
Altered epigenetic modifications, such as histone 
and DNA methylation, can influence chromatin structure 
and help to recruit transcription factors and other 
regulatory proteins to the DNA, thereby regulating gene 
expression [31, 32]. Supporting this notion, IDH mutation 
has been shown to impair KDM4C/JMJD2C, which is 
responsible for demethylation of the repressive histone 
H3K9 di- and trimethylation, alteration of cell lineage 
gene expression, and differentiation arrest in 3T3-L1 cells 
[35]. Moreover, in vitro enzymatic studies have revealed 
that JMJD2A and JMJD2C, two histone H3K9me2/3 
demethylases, are among the enzymes examined most 
sensitive to inhibition by D-2-HG, with IC
50
 of 24 ± 2 
μM and 79 ± 7 μM, respectively [20]. Here, we show 
that elimination of D-2-HG results in the most dramatic 
effect on H3K9 methylation in HT1080 and SW1353 cells, 
while methylation status of other histone lysine residues 
is not significantly altered. These findings indicate that 
KDM4C/JMJD2C is inhibited by D-2-HG accumulated 
in different cancer cells, and that the other histone 
demethylases maybe more resistant to inhibition by D-2-
HG. In addition, we also observed that the TET2-catalyzed 
5 hmC production is inhibited by D-2-HG accumulated in 
HT1080 and SW1353 cells. A partial clearance of D-2-
HG by D2HGDH overexpression in HT1080 cells is not 
sufficient to relieve the inhibition on TET2-catalyzed 5 
hmC production, indicating that TET2 is rather sensitive 
to D-2-HG inhibition. Taken together, our data suggest 
that D-2-HG accumulated in cancer cells inhibits enzymes 
involved in DNA and histone demethylation with high 
selectivity.
Our results show that D-2-HG plays no direct role 
in cell proliferation in routine laboratory culture plates. 
Notably, ectopic expression of D2HGDH which partially 
reduces D-2-HG, does not change histone methylation 
markers and TET2-induced 5 hmC production in HT1080 
cells, yet D2HGDH overexpression effectively inhibits 
the anchorage independent growth and tumor growth 
of these cells. Therefore, the oncogenic role of D-2-HG 
in promoting anchorage-independent cell growth and 
tumorigenicity may be more complex than expected. 
Whether other α-KG-dependent dioxygenases besides 
KDMs and TETs would contribute to the oncogenic 
function of D-2-HG requires further investigation. 
Our observations that D-2-HG is required for tumor 
growth of cancer cells with IDH1/2 mutations suggest 
that inhibition of mutant IDH1/2 could be an attractive 
strategy for therapeutic treatment of cancers with IDH 
mutations. Consistently, inhibition of mutant IDH1 was 
recently reported to have preclinical efficacy in IDH1 
mutant glioma cells and IDH2 mutant AML. In the present 
study, we show that D2HGDH overexpression can reverse 
the oncogenic effects of IDH1/2 mutation. Therefore, 
induction of D2HGDH expression may be another 
potential approach to treat IDH-mutated cancer. Future 
efforts will thus be needed to investigate the molecular 
mechanism of D2HGDH regulation and its potential 
applications as a therapeutic strategy for D-2-HG lowering 
in IDH-mutated tumors.
MATERIALS AND METHODS
Antibodies
Antibodies against D2HGDH (Proteintech, 
13895–1-AP), L2HGDH (Proteintech, 15707–1-AP), 
Flag (Sigma-Aldrich, F1804), Tubulin (Neomarker, MS-
581-P1), β-actin (Genescript, A00702), IDH1 (Epitomics, 
8057–1), H3 (CST, 4499), H3K4me2 (Millipore, 07–030), 
H3K9me2 (Abcam, ab1220), H3K9me3 (Abcam, ab8898), 
H3K27me2 (Abcam, ab1298), H3K27me3 (Millipore, 17–
622), H3K79me2 (Abcam, ab3594), 5 hmC (Active Motif, 
39769), Collagen Type IV (Rockland 600–401-106), HIF-
1α (BD, 610958) and Endostatin (Abcam, ab64569) were 
purchased commercially.
Plasmid construction
Full-length cDNAs of human D2HGDH, L2HGDH, 
and IDH1 were amplified by PCR and then sub-cloned into 
pBABEpuro or pQCXIH vector for retroviral infection. 
Human TET2 cDNA was sub-cloned into pcDNA3 for 
transient transfection. Point mutations of the indicated 
constructions were generated by standard site-directed 
mutagenesis techniques. All constructions were confirmed 
by direct sequencing before further applications.
Cell culture, transfection and stable cell line 
generation
Two sacoma cell lines, HT1080 and SW1353, 
were maintained in Minimum Essential Medium (MEM; 
Gibco) and L-15 medium (Leibovitz), respectively. Both 
medium were supplemented with 10% fetal bovine serum 
(Biological Industries). HEK293T cells were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco) 
supplement with 10% newborn calf serum (Biochrom).
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Plasmid transfection was carried out by 
polyethylenimine (PEI; Polysciences) method, according 
to the manufacturer’s protocol.
Cells stably expressing the indicated proteins were 
established by standard retroviral infection, and selected in 
2 μg/ml puromycin (Ameresco) or 50 μg/ml hygromycin 
B (Ameresco) for 7 days.
Generation of HT1080/IDH1+/– cells by TALEN 
technology
The TALEN target site within the IDH1 gene 
was selected manually and was further confirmed 
by sequencing to exclude polymorphism. The units 
corresponding to 5′-tACGAAATATTCTGGGt-3′ was 
assembled and sub-cloned into pCS2-PEAS vector as the 
left TALE binding site, while the units corresponding to 
5′-tGCAGATAATGGCTTCt-3′ was assembled and sub-
cloned into pCS2-PERR vector as the right TALE binding site.
HT1080 cells were transfected by the indicated 
TALE constructs. 48 hours after transfection, the cells 
were diluted and seeded into 96-well plates. Mono-
clones were marked and grew for verification. To 
further confirm the modification of endogenous IDH1 
gene, genomic DNA was extracted using standard 
phenol/chloroform extraction method and the targeted 
region was amplified and sequenced. Primers used for 
monitoring the TALE editing region were IDH1-T1-F, 
5′-CCATCACTGCAGTTGTAGGTT-3′ and IDH1-T1-R, 
5′-CCAGAAATTTCCAACTTGTATGTGA-3′F.
Western blotting
Cell were lysed in NP-40 buffer containing 150 mM 
sodium chloride, 50 mM Tris at pH 7.4, 0.3% (v/v) NP-40 
and a cocktail of protease inhibitors or lysed directly in 
SDS-PAGE loading buffer. For collagen Type IV protein 
detection, cultured cells were homogenized in a buffer 
containing 200 mM sodium chloride, 20 mM Tris at pH 
7.4, 100 mM glycine, 0.1% (v/v) Triton X-100, 50 μM 
DTT and a cocktail of protease inhibitor. Western blotting 
was performed according to standard protocol.
Metabolite extraction and GC-MS analysis
Post-confluent cells in 6-well plates were 
homogenized in 0.5 ml chilled 80% (v/v) methanol 
containing heptadecanoic acid (Sigma, H3500) as an 
internal standard to monitor batch reproducibility. The 
samples were centrifuged at 12, 000 rpm for 10 min 
and the supernatant was transferred to a high recovery 
glass sampling vial (CNW, VAAP-31509–1232-100) 
to vacuum dry at room temperature. The residue was 
oximated with 30 μl pyridine containing 20 mg/ml 
methoxyamine hydrochloride (Sigma-Aldrich, 226904) 
at 37°C overnight and further derivatized with 20 
μl N-tert-Butyldimethylsilyl-N-methyltrifluoroacetamide 
(Sigma-Aldrich, 394882) at 70°C for 30 min. 1 μl aliquot 
of the derivatized sample was injected into Aligent 
7890A gas chromatography coupled with Agilent 
5975C mass spectrometer. Separation was achieved on 
a HP-5ms fused-silica capillary column (30 m × 250 
μm i.d.; 5% diphenyl - 95% emthylpolysiloxane bonded 
and crosslinked) with helium as the carrier gas at a 
constant flow rate of 1 ml/min through the column. The 
temperature of front injection, MSD transfer interface and 
electron impact (EI) ion source were set to 280°C, 290°C 
and 230°C, respectively. The GC oven temperature was 
set to 100°C for 3 min, with an increment rate of 10°C/
min to 140°C, 8°C/min to 260°C, 10°C/min to 310°C and 
a final 5 min maintenance at 310°C. The electron impact 
ionization was 70 eV. After 5 min of solvent delay, the 
mass data was collected at full scan mode (m/z 50–600).
Measurement of intracellular NADPH and 
NADP+ levels
The intracellular levels of NADPH and NADP+ 
were measured by enzymatic cycling methods as 
previously described [36, 37]. In brief, 1.8 × 106 cells were 
seeded in 10 cm dishes. On the next day, cells were lysed 
in 400 μL of extraction buffer (20 mM NAM, 20 mM 
NaHCO3, 100 mM Na2CO3) and centrifuged at 1, 200g for 
15 min. For NADPH extraction, 150 μL of the supernatant 
was incubated in a heating block for 30 min at 60°C. 160 
μL of NADP-cycling buffer (100 mM Tris-HCl, pH8.0; 
0.5 mM thiazolylblue; 2 mM phenazine ethosulfate; 5 mM 
EDTA) containing 1.3U of G6PD was added to a 96-well 
plate containing 20 μL of the cell extract. After incubation 
for 1 min at 30°C in darkness, 20 μL of 10 mM G6P was 
added to the mixture, and the change in absorbance at 570 
nm was measured every 30 sec for 10 min at 30°C by the 
SpectraMax M5 Microplate Reader (Molecular Devices). 
All the samples were run in triplicate. The concentration 
of NADP+ was calculated by subtracting NADPH (heated 
sample) from total NADP + NADPH (unheated sample).
Measurement of intracellular GSSG and GSH 
levels
Intracellular GSSG and GSH levels were determined 
by using liquid chromatography–mass spectrometry (LC-
MS/MS). In short, cells were harvested by using 80% 
(v/v) pre-cooling (−80°C) methanol and centrifuged at 
4°C at 12000 rpm for 15 min. The supernatants were 
then subjected to LC-MS analysis using a ShimazuLC 
(LC-20AB pump) system coupled with 4000 qtrap 
triple-quadrupole mass spectrometer (AB sciex). A 
Phenomenex NH2 column (50mm × 2.0mm I.D., 5 μm 
particle size, 100Aº) was used. The mass spectrometer 
was optimized and set up in selected reaction monitoring 
(SRM) scan mode for monitoring the M-H of GSSG (m/z 
611.6→306.2) and GSH (m/z 306.2→142.8). The Analyst 
Software was used for analysis.
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DNA dot-blot assay
Genomic DNA was extracted using phenol 
chloroform method and quantified using NanoDrop. DNA 
was serial diluted, spotted on a nitrocellulose membrane 
and crosslinked with the membrane under ultraviolet 
lamp. The membrane was blocked in 5% milk and then for 
subsequent primary and secondary antibodies incubation. 
The membrane was scanned with a Typhoon scanner (GE 
Healthcare). The 5 hmC intensity was quantified by Image 
Quanta software (GE Healthcare).
Gene expression analysis
Next-generation sequencing was performed with 
standard method. Briefly, total RNA was extracted using 
TransZol Up (TransGen). Samples were quantified with 
Agilent 2100 Bioanalyzer. The library preparation and 
RNA sequencing was conducted using Illumina TruSeq 
and Illumina HiSeq 2500 platform (Illumina Inc., San 
Diego, CA).
For sequencing result analyais, after quality 
filtering, paired-end reads were aligned to the human 
reference genome (UCSC hg19) by TopHat software 
(version 2.09) with default parameters except that 
Ensemble GTF gene annotation (-G) (version 63) was 
used to guide the junction reads aligment. Read number 
counting and differentially expressed gene calling were 
carried out by Htseq-count scripts and limma package. 
Three comparisons (i.e. HT1080/IDH1+/– cell putting-back 
IDH1-R132C vs. IDH1-R132C-T77A, IDH1-R132C vs. 
IDH1, and IDH1-R132C vs. vector) were performed and 
differentially expressed genes were filtered with p-value 
less than 0.001. Functional annotation enrichment analysis 
was done by using the DAVID website.
Soft-ager colony formation assay
1.5 ml medium containing 0.5% agar was poured 
into 6-well plates at first and acted as bottom layer to 
segregate the cells from touching with the surface of plate 
bottom. After solidifying, a top layer medium containing 
0.3% agar and 3000 cells was poured. The plates were 
placed in the incubator and the medium was changed 
every 3 days for 30 days. Then the colonies were fixed by 
4% paraformaldehyde in PBS and stained with 0.005% 
crystal violet solution. The colonies larger than 100 μm 
were counted per well. Every group was completed in 
biological triplicate.
Cell proliferation and xenograft studies
Stable HT1080 cells (3 × 104) were seeded in 
triplicate in 6-well plates. The cell number was counted at 
the indicated time points.
Nude mice (male, 4- to 6-week old) were injected 
subcutaneously with stable HT1080 cells (2 × 106). The 
tumor volume was measured each week. The tumors were 
harvested and measured at the indicated time points.
Statistical methods
Results were presented as mean ± SEM unless 
otherwise specified. Statistical analysis is performed using 
a two-tailed unpaired Student’s t-test. The P values less 
than 0.05 were considered significant (* < 0.05, ** < 0.01, 
*** < 0.0001).
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